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Familial Mediterranean Fever (FMF) is associated with
mutation in the gene coding for pyrin which lead to
accentuated innate immune responses involving the IL1
and probably Th1 pathways. We present a teenager who
had FMF and Behçet disease and developed secondary
amyloidosis. We hypothesized that anti-IL1 treatment
would be beneficial for both controlling the disease activ-
ity and maintaining renal function.
A 17 year old girl with FMF (M694V/M694V) and Behcet
disease unresponsive to colchicine (2 mg/day), meth-
otrexate and indomethacine therapy developed proteinu-
ria during her therapy of eight years. She has arthritis,
fever and erythema nodosum as well as aphtous lesions
twice a month. She suffered a poor qualitiy of life and
often unable to attend school. Acute phase reactants, ESR
89 mm/hour, CRP 6.4 mg/dl were high independent of
her attacks. 10 months ago she developed proteinuria of
300 mg/dl proteinuria with dipstick and 1.8 gr/day pro-
teinuria was found. Her renal function tests were nor-
mal.The renal biopsy confirmed the diagnosis of
secondary amyloidosis.
Anakinra was started at 1 mg/kg/day subcutaneously
without stopping colchicine treatment with a special per-
mission from the Ministry of Health. Izoniasid was also
started because of the marked tuberculin reaction. In the
following 6 months the patient was free of clinical symp-
toms. Acute phase reactants decreased. The level of pro-
teinuria did not increase and renal functions remain
stable.
We suggest that secondary amyloidosis due to autoiflam-
matory diseases is a new indication for the use of anti-IL1
treatment.
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